Marloes M. Kleinpenning

Almelo, OV, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.

Journal: Acta dermato-venereologica

Published: December 19, 2024

Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry.

Lower Drug Survival, Less Satisfaction and More Adverse Events in Females Using Biologics for Psoriasis: Results of the Dutch BioCAPTURE Registry.

Journal: Journal of psoriasis and psoriatic arthritis

Published: December 13, 2024

Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.

Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.

Journal: American journal of clinical dermatology

Published: April 28, 2024

Frailty and functional dependency in a multicenter cohort of older adults with psoriasis: Prevalence and extent of and implications for psoriasis management.

Frailty and functional dependency in a multicenter cohort of older adults with psoriasis: Prevalence and extent of and implications for psoriasis management.

Journal: Journal of the American Academy of Dermatology

Published: March 05, 2024

Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry.

Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry.

Journal: The Journal of dermatological treatment

Published: January 24, 2024

Exclusion by age, cardiovascular comorbidity and malignancies are the main factors that impact generalizability of evidence from trials to the real-world situation in older adults with psoriasis.

Exclusion by age, cardiovascular comorbidity and malignancies are the main factors that impact generalizability of evidence from trials to the real-world situation in older adults with psoriasis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 06, 2023

Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study.

Safety Assessment of Conventional and Biological Systemic Therapy in Older Adults with Psoriasis, a Real-world Multicentre Cohort Study.

Journal: Acta dermato-venereologica

Published: September 06, 2022

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study.

Journal: Drugs & aging

Published: June 08, 2022

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.

Journal: Acta dermato-venereologica

Published: March 31, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026